KYMR 250117 22.50P (KYMR250117P22500) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

KYMR250117P22500

Watchlist

1.95
0.000.00%

15min DelayClose Jan 10 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

Stifel Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $56
Moomoo NewsJan 8 06:31 ET · Ratings
Kymera Therapeutics: Promising Prospects With Targeted Protein Degradation and Innovative Drug KT-621
TipRanksJan 8 06:26 ET
Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14
GlobeNewswireJan 7 07:00 ET
Brookline Capital Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Cuts Target Price to $97
Moomoo NewsJan 6 11:32 ET · Ratings
Jefferies Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $59
Moomoo NewsJan 2 10:32 ET · Ratings
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Kymera Therapeutics (KYMR) and Sarepta Therapeutics (SRPT)
TipRanksJan 2 10:20 ET · Ratings

Comments

Spinee

Jul 15, 2024 02:41

XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details

These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio?
$XPeng (XPEV.US)$ stock rose 15.56%. Shares of Chinese stocks gained following an increase in China's June exports.
$QuantumScape (QS.US)$ stock jumped 64.34% after the company announced it entered into an agreement with Volkswagen $VOLKSWAGEN A G (VWAGY.US)$ 's battery company PowerC...

Meltyy

May 16, 2024 01:14

🔔 Baker Bros. Q1 ‘24* Holdings Released... 🐳

» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte (INCY.US)$
$BeiGene (BGNE.US)$
$ACADIA Pharmaceuticals (ACAD.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Revolution Medicines (RVMD.US)$
$Kymera Therapeutics (KYMR.US)$
$AbCellera Biologics (ABCL.US)$
$Bicycle Therapeutics (BCYC.US)$
$Edgewise Therapeutics (EWTX.US)$
$Immunocore (IMCR.US)$
$Kodiak Sciences (KOD.US)$
$Roivant Sciences (ROIV.US)$
...

Moomoo AI

Feb 25, 2024 07:56

Despite lower revenue forecasts, analysts see no long-term impact on the business's intrinsic value. Opinions vary, with the most optimistic analyst valuing it at US$112 and the most pessimistic at US$26.00 per share. No changes were made to next year's loss forecasts, but revenue estimates were downgraded. The company's long-term earnings trajectory is deemed more crucial than next year's performance.

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Analysts Are Pretty Bullish On The Stock After Recent Results

Moomoo AI

Dec 27, 2023 04:53

Kymera Therapeutics' high P/S ratio could imply investors' bullish stance outweighs analysts. However, without major growth improvement, the high P/S value may not sustain this positive sentiment, potentially making the stock overvalued.

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 35% Price Boost Is Out Of Tune With Revenues

Trytosaveabit

Dec 7, 2023 06:09

Update

$Kymera Therapeutics (KYMR.US)$ Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment From Sanofi